Cognition Therapeutics has reached agreement with the FDA on the design of a pivotal Phase 3 trial of oral Zervimesine (CT1812) in mild-to-moderate dementia with Lewy bodies, with hallucinations and delusions as the primary endpoint and daily function as a key secondary measure. Nine-month dosing at 100 mg once daily will test whether earlier Phase 2 signals across neuropsychiatric, cognitive, motor and functional domains hold in a registrational setting. No approved therapy currently slows progression of the disease, which affects an estimated 1.4 million Americans.
Key Points
- FDA aligned on pivotal Phase 3 design for oral Zervimesine in DLB
- Primary endpoint measures hallucinations and delusions over nine months
- No approved disease-modifying therapy exists for dementia with Lewy bodies
Longevity Analysis
Neurodegenerative decline rarely announces itself through cognition alone; in Lewy body disease the earliest and most destabilizing signals are perceptual and behavioral, which is why a hallucination-and-delusion endpoint carries practical weight for both patients and caregivers. Targeting the cellular machinery that governs protein handling and synaptic maintenance places this candidate alongside interventions aimed at preserving neural repair capacity rather than masking symptoms. For clinicians, the trial's structure offers a useful template for evaluating any intervention intended to alter trajectory rather than manage the downstream expression of a failing system.
Original published by LT Wire.